We believe that everyone - irrespective of who they are or where they live - deserve medications that work We believe that everyone - irrespective of who they are or where they live - deserve medications that work

310 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking the next generation of mRNA medicines. At Sensible, we are building the best-in-class mRNA design, optimisation and manufacturing platform to unlock the era of mRNA therapeutics and design-based biology.

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Selvita is one of the largest preclinical contract research organizations in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development. biotechnology, pharmaceuticals, drug discovery, preclinical research, bioanalytical development services, bioinformatics, systems biology, proteins, genomics, proteomics, autoimmune disorders, regulatory studies, medicinal chemistry, agrochemical, industrial chemistry, and assay development&screening

514 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Altamira is developing peptide-based nanoparticles (xPhoreTM) for delivery of nucleic acids to extrahepatic tissues. Altamira Therapeutics is developing and supplying peptide-based nanoparticles (xPhoreTM) for delivery of nucleic acids to extrahepatic tissues. This versatile technology is suited for delivering different nucleic acid modalities: OligoPhoreTM for small RNAs (siRNA/ASO), SemaPhoreTM for mRNA, CycloPhoreTM for circRNA and GenePhoreTM for DNA. xPhoreTM is licensed to pharma and biotech companies for use with their proprietary nucleic acid molecules. The Company currently has two proprietary siRNA programs using OligoPhoreTM in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for …

63 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

An early-stage oncology company aiming to treat solid tumors SOLID Therapeutics is an early-stage oncology company spun out of CBMR at the University of Copenhagen. We are developing novel cancer therapeutics with dual mode of action targeting both cancer cells and immune cells to treat solid tumors.

81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Revolutionizing drug delivery HHC medical is a health tech startup developing a platform technology for targeted and non-invasive drug delivery via wireless electroporation. Drug Delivery, Genetic therapies, and Enabling life-altering therapies

296 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Synthetic Biology

Transforming Rare Respiratory Disease Outcomes Using Inhaled Genes Therapy AlveoGene is an innovative company focused on transforming rare respiratory disease outcomes using inhaled gene therapy. AlveoGene has been created by OSE, Harrington and OCC in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC). The GTC was founded in 2001 to catalyse the application of pioneering research to gene therapy development and manufacturing related to cystic fibrosis and other respiratory diseases, and originated at Imperial College London and the Universities of Oxford and Edinburgh. AlveoGene has secured an exclusive licence to a proprietary and validated …

59 similar entities Type: Startup Activities: manufacturing deeptech biotech Technologies: Synthetic Biology

Developing revolutionary biomaterials for regenerative medicine. Spiderwort Inc. is a tissue engineering company specializing in the development of transformative biomaterials for repairing and regenerating tissues within the human body.

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Harnessing the Power of Tumor Gene Therapy to Turn the Tide in the Battle Against Cancer Headquartered in Cambridge, Massachusetts, Akamis Bio is a clinical-stage oncology company developing systemically administered immunotherapies to treat solid tumors, initially in patients with locally advanced rectal cancer (LARC). Its proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform is designed to deliver novel immunotherapeutic proteins, biomolecules and transgene combinations to treat solid tumors, with its lead clinical-stage program, NG-350A, driving intratumoral expression of a CD40 agonist monoclonal antibody. To learn more, please visit www.akamisbio.com Immuno-oncology and Re-programming the Tumor Microenvironment

113 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Ion channel and GPCR drug discovery using innovative KnotBody technology Maxion uses its innovative KnotBody technology in combination with in vitro display technologies to generate therapeutic candidates against ion channels and GPCR proteins.

152 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

NeoDynamics was a publicly listed medical device company specializing in breast cancer diagnostics. Its flagship product, the NeoNavia Biopsy System, was acquired by NeoNavia AB. Following this transaction, NeoDynamics AB (publ) now operates under the name Gardienne Invest AB (publ).

59 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Delivering longer, better quality lives for brain tumour patients QV Bioelectronics is a VC-backed medical device startup developing an implantable electric field therapy treatment for aggressive brain tumours.

114 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Humane Genomics develops cancer therapies by engineering cancer-killing RNA viruses using a synthetic biology platform Humane Genomics is developing a platform to engineer cancer killing viruses with unprecedented specificity and efficiency. Our first indication is liver cancer. We are based in New York City and backed by amazing investors. (YC S21)

109 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We develop cancer immunotherapy with our unique mRNA delivery technology Vectiopep is developing peptide-based nucleic acid delivery technology. Combined with the new generation mRNA therapeutics, we empower the body's immune system to fight cancer. Vectiopep is a privately-held biotechnology company, founded by a group of researchers who have more than 10 years of expertise in developing and optimizing delivery technologies for nucleic acids..

Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Orchestrating gut health® EnteroBiotix is a leading microbiome therapeutics platform company that is focussed on transforming the standard of care for patients battling debilitating diseases and infections linked to disruptions to structure and function of the gut microbiome.

143 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Making Regenerative Medicine Accessible Roumai Medical is developing next-generation biotechnologies in regenerative medicine and human-machine interface to meet the unmet clinical needs of millions of patients worldwide.

207 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Focused on the development of precisely targeted, controlled & highly active T cell therapies for cancer Autolus is a CAR T cell therapy company. We are applying our extensive programming capabilities to develop advanced autologous T cell therapies that have the potential to deliver life-changing therapies to patients with cancer and autoimmune diseases.

75 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming the lives of patients through gene therapy uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases. aav, Huntington's disease, gene therapy, ALS, epilepsy, and Fabry disease

257 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Building on innovative science to create treatments for patients in need ResoTher Pharma ApS is a biotechnology company focused on developing novel and effective peptide therapeutics for cardiovascular disease by targeting inflammation. Biotechnology, Drug Development, and Pharmaceutical Industry

535 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

a wholly owned subsidiary of Eli Lilly and Company LimmaTech Biologics AG, a wholly owned subsidiary of Eli Lilly and Company, is a Swiss-based clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to emerging antibiotic resistance (AMR) and sexually transmitted diseases. vaccines, research & development, biotechnology, and antimicrobial resistance

419 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We’re using ground-breaking cell technologies to revolutionise global food production - starting with pork Uncommon Bio began with cell-based meat and pioneered RNA delivery innovations, which evolved into their most recent spin out which is focusing on changing medicine through multi-targeting. Their polysaccharide-based delivery platform enables multi-pathway cell programming, offering a safe, efficient and scalable alternative to multi-target therapies. The company is initially targeting severe lung diseases like idiopathic pulmonary fibrosis and is backed by industry leaders from BioNTech and top investors, including Sam Altman, Balderton, Lowercarbon, and Redalpine. science+art, biotech, mRNA, IPF, Pulmonary fibrosis, and delivery

561 similar entities Type: Startup Activities: biotech deeptech foodtech Technologies: Synthetic Biology

Technology to ignite the biology revolution We are a Cambridge-based company developing a radically different approach to gene synthesis. Our desktop DNA synthesis platform will provide the ability to synthesise DNA at unprecedented accuracy, scale and speed, accelerating scientists'​ ability to use synthetic biology on a scale not currently possible. Biotechnology, Synthetic Biology, DNA synthesis, Gene synthesis, and synbio

132 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We care about everybody's health Arterra Bioscience is a biotech company listed on the “Euronext Growth Milan” market of Borsa Italiana since 2019, founded in Naples by M. Gabriella Colucci in 2004 with the aim of developing technologies and innovative solutions that find application in various industrial sectors. Arterra is a company strongly linked to the Campania region from which it derives the natural raw materials underlying many of its actives, as well as being able to take advantage of the ideas and enthusiasm of its young researchers. Biotechnology, R&D, Cosmetics, medical Device, Agriculture, and Agrifood

68 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

TECregen is dedicated to advancing immuno-rejuvenation by developing next generation therapies to regenerate the thymus. TECregen is pioneering thymus rejuvenation to address conditions driven by impaired T-cell responses. The company’s innovative approach focuses on revitalizing and expanding thymic epithelial cells (TECs) to replenish T cells and achieve durable improvements in immune function. By developing a pipeline of differentiated thymopoietic biologics, TECregen aims to strengthen immune recovery following transplantation or cytotoxic therapy, promote immune health, and enhance immune surveillance against cancer, ushering in a new era of immunotherapy.

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Targeting synthetic lethality in cancer Eisbach Bio is an innovative start-up in biotechnology founded in 2019 as a spin-out of the Biomedical Center Munich. We are developing novel drugs that successfully target molecular vulnerabilities arising in cancer genomes. Eisbach will beat cancer at its own game.

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Swedish biotech company exploring reprogramming as the next leap forward in cancer immunotherapy Asgard Therapeutics is a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy. The company builds on ground-breaking and proprietary reprogramming technologies to develop gene therapy products designed to set in motion efficient and personalized immune responses. Backed by top investors, Asgard Therapeutics aims to establish a pipeline of off-the shelf cancer immunotherapies that trigger personalized anti-cancer immune responses for the benefit of cancer patients in need. Cell Reprogramming, Cancer Immunotherapy, and Dendritic cells

82 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Redefining Synthetic Lethality beyond HRD Tessellate BIO discovers and develops novel precision oncology medicines with the mission to turn cancer patients into cancer survivors. A private preclinical stage biotechnology company, Tessellate BIO is redefining Synthetic Lethality by developing drugs that target unexplored or difficult to drug pathways beyond HRD. Headquartered in the Netherlands and with research labs at the Stevenage Bioscience Catalyst, UK, Tessellate BIO is supported by top-tier life science investors BioGeneration Ventures (BGV) and Forbion. drug discovery, precision oncology, and biotechnology

67 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Exploiting a new class of tumour specific antigens for cancer therapy A newly established NewCo developing therapeutics targeting a novel class of tumour-specific antigen. TCR-T cells, Immuno-oncology, Vaccines, Bi-specifics, Splicing, Epigenetics, Oncology, T cell biology, and Antigen presentation

178 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Ilya Pharma 🇸🇪🇺🇸 is bringing local-acting immunotherapies to patients Delivering local-acting immunotherapies to patients ATMP, Gene Therapy, Drug development, Clinical trials, GMP, IBD, Wound treatment, Scar, Topical, Oral, Research, Science, Immunology, Immunophysiology, microbiology, Applied microbiology, Regulatory excellence, Skin, Diabetes, IBD, Cysticfibrosis, SAVI, colitis, Cystic fibrosis, and Inhalation

646 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Turning Cancer’s Energy Dependency Against Itself: a Shift in Precision Drug Delivery INATHERYS is a clinical-stage biotech advancing precision drug delivery, turning cancer’s energy dependency against itself. Our lead asset, an ADC targeting CD71/TfR1, is designed to address critical needs in treating proliferative cancers.

123 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

New therapeutic targets based on arsenic trioxide (As2O3) Founded in 2010, MEDSENIC is a biopharmaceutical start-up that aims to exploit the new possibilities offered by the therapeutic use of arsenic trioxide (As2O3) and thereby provide a treatment for patients with autoimmune diseases. santé, biotechnologies, bioparma, biopharmaceutical, biotech, health, biotechnology, autoimmune diseases, and maladies auto-immunes

259 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Translation-X is a biotech company developing novel, targeted therapeutics for neurodevelopmental disorders. Translation-X is a spin-off project at the Biozentrum, University of Basel. We are developing novel pharmacological tools to reduce core symptoms of autism by targeting RNA translational machinery.

63 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Changing the paradigm in Friedreich's ataxia Biointaxis is an academic spin-off focused on the development of gene therapies for neurodegenerative disorders. Biointaxis lead product is a gene therapy product for Friedreich ataxia.

59 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Advancing precision oncology therapeutics designed to deploy multi-faceted inhibition to reverse cancer resistance AUM Biosciences is focused on advancing a clinical pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance biotech, oncology, drug development, Asian-biotech, Precision medicine, Digitalhealth, cancer, and small molecules

370 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Sustainable circular-derived protein | Clean-label ingredients for alt-protein & cultivated meat | High Quality Cells An ingredients company providing sustainable, scalable and delicious solutions for alternative protein and cultured meat.

70 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Humanigen, Inc. (HGEN) is a clinical-stage biopharmaceutical company seeking to transform the treatment of cancers and infectious diseases, including COVID-19, by preventing and treating cytokine storm via its novel, cutting-edge anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody neutralization and gene-knockout platforms. Its proprietary Humaneered® monoclonal antibodies, designed to optimize antibody properties, show promise in prevention/treatment of cytokine storm induced by SARS-CoV-2 (COVID-19), chimeric antigen receptor T-cell (CAR-T) therapy and graft versus host disease (GvHD) by neutralizing GM-CSF which is up-regulated in these conditions.

61 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

StemTek Therapeutics is a start-up biotechnolgy company dedicated to accelerating drug discovery in cancer using cutting edge technology, world-class science and a stem cell centric point of view for cancer therapy. Our mission is to help design novel treatments for cancer targeting cancer stem cells.

107 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Follow Astellas Pharma for updates on our pipeline of genetic medicines for patients with rare diseases. The Astellas Gene Therapies page is no longer active or monitored. gene therapy and biotechnology

81 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Bio-Gene is an Australian agtech company enabling the next generation of novel insecticides. Follow our journey. Bio-Gene is an Australian AgTech company that produces a range of patent-protected platforms, QCIDETM and FlavocideTM, targeted at the insecticides market. These technologies have a novel mode of action that offer a new range of effective insecticides that are safe for consumers. insecticides derived from nature and Insecticides

55 similar entities Type: Startup Activities: deeptech biotech Technologies: SaaS

Peptide Chemistry company for design, synthesis, stability studies and chemical optimisation (SAR studies)- CIR agrement PEPTIDES, PEPTIDE LIBRARIES AND PROTEINS Innovative chemistry for therapeutic, diagnostic and cosmetic applications GENEPEP is a CRO company (with CIR agreement) focused on peptide synthesis & services : - Tools for nanoparticles & surface functionalization - Custom synthesis of peptides, proteins & peptide libraries - Catalog of toxins, peptides & pseudopeptides - Design & synthesis for SAR studies (optimisation of solubility, stability, efficacy,...) - Stability & solubility tests - Partner of European programs, ANR, FUI etc...

132 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel multispecific antibody technology to harness the body's immune system to bring breakthrough treatments to patients. In addition to its wholly owned clinical assets, Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platform, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas. For more information, email info@dragonflytx.com. immuno-oncology

94 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A Member of the Roche Group Poseida was acquired by Roche in early 2025 and is now part of the Roche Group. Poseida is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure. The Company's approach is based on its proprietary genetic editing platforms, including its non-viral DNA Delivery System, Cas-CLOVERTM Site-Specific Gene Editing System, Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing. Genome Engineering, CAR-T cells, Gene Therapy, Gene Editing, Cell Therapy, Adoptive Cell Therapy, Multiple Myeloma, Prostate Cancer, Transposon, Non-viral, Biotechnology, Immunotherapy, Regenerative …

88 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Powering the next wave of genetic medicines through superior delivery ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. RNA Therapies, Genetic Medicines, Non-Viral Lipid Nanoparticles, Genetic Respiratory Disease, Cystic Fibrosis, Primary Ciliary Dyskinesia, and Biotechnology

148 similar entities Type: Startup Activities: deeptech biotech nanotech Technologies: Synthetic Biology

Advancing iPSC-derived cell therapies to transform care in autoimmune disease and cancer​ Century Therapeutics is an innovative biotechnology company that is building an industry-leading, allogeneic, iPSC-derived cell therapy platform that integrates cutting-edge gene editing, protein engineering, technical development and manufacturing capabilities to generate allogeneic, iPSC-derived therapies for autoimmune diseases and cancer.​ Please note: Century Therapeutics does not solicit prospective Colleagues directly via Telegram (or other social media sites) or require potential candidates to make purchases of goods or services.​

65 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Delivering Hope to the Heart of our Patients AuriGen Medical are an EUeic supported medical device start up, developing the next generation in left atrial appendage implant technology for the treatment of medication resistant longstanding persistent atrial fibrillation. #EUeic #eicAccelerator

93 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

coIMMUNE is a privately held, clinical stage immune-oncology company that will redefine cancer treatment using best-in-class cellular immunotherapies. Our allogeneic CAR-CIK technology platform for liquid and solid tumors is a novel CAR therapy that promises enhanced efficacy with greatly reduced toxicity.

110 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing technology for tomorrow's crops AgGene is an agriculture biotechnology company focused on the development of plant traits to address major challenges faced during crop production. Our flagship technology addresses the demand for improving protein content in plant tissues using advanced genomics and molecular plant breeding techniques including gene-editing. AgGene is also focused on collaborative relationships with other agriculture companies and independent plant breeders to help develop plant biotech traits to address issues including climate resilience. biotechnology, gene editing, agriculture, molecular genetics, molecular biology, genomics, genetic engineering, and plant biology

66 similar entities Type: Startup Activities: biotech deeptech agritech Technologies: Synthetic Biology

Technology-driven biotech with an AI-powered miniprotein RnD platform VRG Tx is technology-driven biotech with a drug discovery platform that integrates AI with wet lab processes to develop next-generation therapeutics. Our vision is to cure diseases through previously undruggable targets and inaccessible mechanisms of action. medicinal biotechnology, research, immunology autoimmune deases , translational health research, use of genetic engineering in medicine, anti cancer drug discovery, oncological drugs, autoimmune diseases, translational research, peptide, cellandgenetherapy, and genetherapy

589 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Molecular Glues by Design TernaryTx, a pioneering biotech startup, with a revolutionary AI-driven platform for designing molecular glue therapeutics, opening new frontiers in drug discovery for previously "undruggable" targets.

79 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology A.I. A.I. - Machine Learning

Premium quality preclinical oncology CRO, pioneering the PDX technology for more than 20 years. XenTech is Biotech/Contract Research Organization (CRO) dedicated to translational research in oncology which offers preclinical services to evaluate the anti-cancer potential of drug candidates (PDX, CDX,...) In addition, XenTech develops internal R&D programs to correlate drug response with molecular features of tumors and identify cancer biomarkers and therapeutic targets. patient-derived tumor xenograft models, oncology, biomarkers, efficacy preclinical studies, PDX, CDX, in vivo, and in-vitro assays

61 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering Antibody Innovations to Defeat Cancer At VERAXA Biotech (NASDAQ:VRXA), we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including antibody-drug conjugates (ADCs), bispecific T cell engagers (BiTAC TCEs), and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA Biotech was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technologies. Cancer Research, Drug Development, …

192 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Oak Hill Bio's mission is to develop life-changing medicines for patients suffering from rare diseases Oak Hill Bio is a clinical-stage biotech company committed to developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases.

Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The RNA Platform - by analyzing RNA we can detect disease, monitor health and design the Next Generation Cures Today only 1 out if 4 cancer drugs prolongs life because we treat all the patients the same way. Genomic Expression’s OneRNATM test can save lives and make healthcare delivery more effective by sequencing RNA and linking RNA’s to approved therapies and clinical trials. Genomics, information, personalized medicine, personalized diagnostics, Sequencing, prognostics, bioinformatics, sample preparation, Next Generation Sequencing, Biobank, Access to biological samples, target filtering, RNA-seq, RNA sequencing, and RNASeq of FFPE samples

138 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing the Next Generation Gene Editing Technology Pencil Biosciences is developing a truly innovative gene modulation technology that can have an impact across a range of applications, including new therapeutic options for patients with rare diseases. Genome Engineering, Research and Development, and Gene Editing

183 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Engineering the Next Generation of Therapeutics Molecular Templates, Inc. (MTEM) is a clinical stage biopharmaceutical company focused on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform with unique mechanisms of actions which are highly differentiated from antibody drug conjugates (ADCs). MTEM is developing MT-6402, which is in a Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients; MT-5111, which is in a Phase I clinical trial for the treatment of HER2-positive cancers; and MT-0169, …

74 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

UNITY is harnessing pathways of aging biology to develop new medicines, with a focus on retinal diseases. As pioneers in cellular senescence, UNITY is advancing the first senolytic therapeutic candidate for retinal diseases that aims to restore diseased tissue to a healthier state, a potentially paradigm shifting treatment in ophthalmology.

66 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Revolutionizing the storage and delivery of vaccines and therapeutics. We are a biotechnology company revolutionizing vaccines and biologics by removing all cold storage requirements and expediting manufacturing.

97 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Securing your vision Recornea is a clinical stage medtech ophthalmic company developing therapeutic solutions for treating diseases of the cornea, such as keratoconus, glaucoma and corneal transplants.

110 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Seeking to improve lives through the curative potential of gene therapy. REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with …

64 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology SaaS

Clinical-stage biopharmaceutical company developing transformative therapies to treat devastating human diseases Caribou Biosciences is a leading clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Our next-generation genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. We believe the future of cell therapy is off-the-shelf, and we are advancing our pipeline of off-the-shelf, or allogeneic, cell therapies from our CAR-T cell therapy platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases. Next-generation CRISPR genome editing, allogeneic CAR-T cell therapies, oncology, and …

100 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Living Immunotherapies Medigene AG (FSE: MDG1) is a leading immuno-oncology platform company dedicated to developing T-cell therapies to effectively eliminate cancer. Its end-to-end technology platform is built on multiple proprietary exclusive product development and product enhancement technologies, and allows Medigene to create best-in-class differentiated, T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering. For more information, please visit www.medigene.com Immunotherapies and T Cell receptors TCR

85 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Ovagen is a biotechnology company that has developed a proprietary process of producing Germ Free chicken eggs and Germ Free birds in commercial quantities for use primarily in the vaccine and pharmaceutical industry.

70 similar entities Type: SMB Activities: pettech healthtech Technologies: Synthetic Biology

Lontra Ventures is an Austin, Texas based entrepreneurial consultancy with two core specialties: Life Science Consulting: Specialty Drug Commercialization & Selling Value Added Services to Pharmaceutical Manufacturers Technology: Business Development & Strategic Sales for High-Growth Companies

64 similar entities Type: SMB Activities: biotech consulting Technologies: Synthetic Biology

A Technology Development and Advisory Company Focused on Medical Devices/Biologics Strategic Advisory Services for both large & small medical device/biologics companies including acquisition, licensing, distribution, joint venture agreements Market, Scientific and Clinical Due Diligence Services Business development Services for venture capital, private equity, hedge funds and investment banking clients & their portfolio companies and clients Product/Device development Strategic Product Postioning including licensing, distribtution and market positioning New Company Formation

142 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Precision Radiotherapy From Within BetaGlue Therapeutics is a clinical stage oncology company that has developed an advanced radiotherapy platform enabling localised targeted treatment of both unresectable solid tumours and also treatment of surgical resection margins called YntraDose. radiotherapy, nuclear medicine, oncology, and medical devices

207 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing next-generation lipid nanoparticle delivery systems to unlock the potential of RNA therapeutics Axelyf was founded in Iceland in 2022 with the goal of harnessing health benefits of natural molecules through chemistry and delivery engineering.

169 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology